Government gears for unprecedented challenge of Eli Lilly antibody rollout as efficacy questions linger
After months of anticipation, the FDA has authorized the first antibody treatment for Covid-19. Now what?
The US government faces a challenge unlike virtually any it has faced during or before the pandemic. They will have to distribute scarce quantities of a much-sought drug throughout the country at a time when cases are reaching record levels, overburdening hospitals to the point where, in North Dakota, Covid-19 positive nurses have been authorized to continue working.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.